CoLucid Pharmaceuticals (CLCD) IPO Opens Down 15%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
May 6, 2015 9:00 AM EDTBURLINGTON, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. ("CoLucid") (Nasdaq: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.
In addition, CoLucid has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering... More
